N-acetylcysteine reduces malondialdehyde levels in chronic hemodialysis patients--a pilot study
| Autor: | M Schropp, H Pereyra, M R Mongitore, M Forrester, E. Freixas, H Trimarchi, M Alonso, P Baglioni |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Antioxidant medicine.medical_treatment Pilot Projects medicine.disease_cause Gastroenterology Acetylcysteine Lipid peroxidation chemistry.chemical_compound Renal Dialysis Internal medicine Malondialdehyde Medicine Humans Dialysis business.industry General Medicine Glutathione Free Radical Scavengers Middle Aged Surgery Oxidative Stress chemistry Nephrology Female Hemodialysis business Oxidative stress medicine.drug |
| Zdroj: | Clinical nephrology. 59(6) |
| ISSN: | 0301-0430 |
| Popis: | Background: Oxidative stress has been implicated in the development of en- dothelial damage in hemodialysis (HD). We have assessed the effects of N-acetylcysteine (NAC), a compound with antioxidant effects, on malondialdehyde (MDA), a marker of oxi- dative stress on lipid peroxidation. Methods: A clinical trial was conducted in which 24 chronic HD patients were divided into 2 groups according to gender, age, time on HD and cause of renal failure. The NAC group (n = 12) received 600 mg of NAC twice a day for 30 days. The remaining patients consti- tuted the control group (n = 12). MDA levels were measured pre- and post-dialysis at the beginning of the study (baseline) and on day 30 (30 days). Results: Baseline pre- and post- dialysis MDA levels were not different be- tween both groups and were above normal values. A significant decrease was found in the NAC group when either pre- or post- dialysis MDA levels were compared to the corresponding control group levels on day 30 (pre-dialysis NAC vs control group 3.01 ± 0.6 vs 4.5 ± 0.73 mol/l, p < 0.0001, post-dialysis NAC vs control group 2.76 ± 0.5 vs 4.39 ± 0.7 mol/l, p < 0.0001). Only in the NAC group were pre-dialysis MDA 30-day levels differ- ent from pre-dialysis baseline levels (3.01 ± 0.6 vs 5.07 ± 1.6 mol/l, p < 0.002). Post- dialysis MDA 30-day concentrations were significantly lower than post-dialysis MDA baseline levels (2.76 ± 0.5 vs 4.32 ± 0.7 mol/l, p < 0.002) and pre-dialysis MDA 30-day measurements (2.76 ± 0.5 vs 3.01 ± 0.6 mol/l, p < 0.011). Conclusions: MDA levels are elevated in chronic HD patients and are not significantly reduced by HD. NAC significantly reduces malondialdehyde levels in chronic HD patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|